Experimental cell therapy tested for Tough-to-Treat blood cancers
NCT ID NCT04620681
Summary
This study tested the safety of a new type of donor immune cell infusion for patients with advanced myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) after their initial treatments stopped working. The goal was to see if these specially prepared cells from an unrelated donor could help control the disease without causing severe side effects. The trial enrolled 19 adult patients to find the safest dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.